| Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals | 
| Synonyms Flotegatide F18, RGD F18, RGD-F18 | 
| Target | 
| Action stimulants | 
| Mechanism αvβ3 stimulants(Integrin alpha-V/beta-3 stimulants) | 
| Therapeutic Areas | 
| Active Indication- | 
| Inactive Indication | 
| Originator Organization | 
| Active Organization- | 
| Inactive Organization | 
| License Organization- | 
| Drug Highest PhaseDiscontinuedPhase 2 | 
| First Approval Date- | 
| Regulation- | 
| Molecular FormulaC41H60FN13O13 | 
| InChIKeySDQRGILXNZSUMD-ABRGNQFASA-N | 
| CAS Registry1010702-75-6 | 

| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Advanced Head and Neck Carcinoma | Phase 2 | France  | 20 Mar 2015 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | France  | 20 Mar 2015 | |
| Carotid Stenosis | Phase 2 | United States  | 01 May 2012 | |
| Breast Cancer | Phase 2 | United States  | 01 Sep 2009 | |
| Colorectal Cancer | Phase 2 | United States  | 01 Sep 2009 | |
| Non-Small Cell Lung Cancer | Phase 2 | United States  | 01 Sep 2009 | |
| Glioma | Phase 1 | United States  | 01 Aug 2008 | |
| Melanoma | Phase 1 | United States  | 01 Aug 2008 | |
| Sarcoma | Phase 1 | United States  | 01 Aug 2008 | |
| Atherosclerosis | Preclinical | United States  | - | 





